Invivyd, Inc. (NASDAQ:IVVD) Director Sells $45,261.18 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 83,817 shares of the firm’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $0.54, for a total value of $45,261.18. Following the sale, the director now directly owns 3,340,520 shares of the company’s stock, valued at approximately $1,803,880.80. This trade represents a 2.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 23rd, Terrance Mcguire sold 75,776 shares of Invivyd stock. The shares were sold at an average price of $0.45, for a total transaction of $34,099.20.
• On Friday, December 20th, Terrance Mcguire sold 119,805 shares of Invivyd stock. The shares were sold at an average price of $0.42, for a total transaction of $50,318.10.
• On Wednesday, December 18th, Terrance Mcguire sold 74,764 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total transaction of $35,139.08.
• On Monday, December 16th, Terrance Mcguire sold 65,359 shares of Invivyd stock. The stock was sold at an average price of $0.47, for a total value of $30,718.73.
• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The shares were sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

Shares of Invivyd stock traded up $0.02 during trading on Thursday, hitting $0.53. 870,708 shares of the stock were exchanged, compared to its average volume of 667,876. The firm’s 50-day moving average price is $0.74 and its 200 day moving average price is $0.99. The stock has a market cap of $63.44 million, a price-to-earnings ratio of -0.27 and a beta of 0.53. Invivyd, Inc. has a 12-month low of $0.40 and a 12-month high of $5.20.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Duquesne Family Office LLC acquired a new position in Invivyd in the second quarter valued at approximately $629,000. Acadian Asset Management LLC grew its position in Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after purchasing an additional 474,301 shares during the last quarter. Cornercap Investment Counsel Inc. acquired a new position in Invivyd in the 2nd quarter valued at about $86,000. Cubist Systematic Strategies LLC increased its holdings in shares of Invivyd by 66.1% in the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the period. Finally, SG Americas Securities LLC raised its position in Invivyd by 198.6% during the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after buying an additional 25,201 shares during the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Analyst Upgrades and Downgrades

IVVD has been the subject of several recent research reports. HC Wainwright lowered their price objective on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. EF Hutton Acquisition Co. I raised shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a research note on Thursday, November 21st. Finally, Morgan Stanley reduced their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.